Enorama Pharma AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company is mainly focused on the development of medical chewing gum that contains drugs. The Company's product Nicotine gum is a chewing gum contained drugs that help to overcome nicotine addiction. In addition, the medical chewing gum applications include pain management, allergy, cough and cold, among others. The Company distributes its products in Europe through pharmacy chains and grocery stores.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-22	SEK 0.8740	-17.55%	116,762
26-10-21	SEK 1.060	+32.17%	221,845
26-10-20	SEK 0.8020	-19.15%	124,366
26-10-19	SEK 0.9920	-17.33%	170,948
26-10-16	SEK 1.200	+1.27%	505,397

Delayed Quote Nasdaq Stockholm

More quotes

Market Closed - Nasdaq Stockholm 12:00:00 2026-10-22 EDT			5-day change	1st Jan Change
0.8740 ^SEK	-17.55%		+19.73%	-54.24%

08-19	Enorama Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-19	Calendar Wednesday, August 19	FW

Market Cap	79.06M 7.97M 7.11M 6.56M 5.96M 11.19M 755M 11.36M 31.14M 396M 29.92M 29.28M 1.25B	P/E 2024	-4.07x	P/E 2025	-1.77x
Enterprise Value	76.03M 7.66M 6.84M 6.31M 5.73M 10.76M 726M 10.92M 29.95M 380M 28.77M 28.15M 1.2B	EV / Sales 2024	12.8x	EV / Sales 2025	50.9x
Free-Float	8.88%	Yield 2024 *	-	Yield 2025	-

08-19	Enorama Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-19	Calendar Wednesday, August 19	FW
08-18	Calendar Wednesday, August 19	FW
06-16	Calendar Tuesday June 16	FW
06-15	Calendar Tuesday June 16	FW
06-12	Calendar Monday June 15 - Friday June 19	FW
05-20	Enorama Pharma sells nicotine gum business assets to Aflofarm	RE
05-20	Enorama Pharma Q1 operating loss narrows to SEK 10.9 mln	RE
05-20	Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Calendar Wednesday May 20	FW
05-19	Calendar Wednesday May 20	FW
04-23	Enorama Pharma AB Auditor Raises 'Going Concern' Doubt	CI
04-02	Financial Calendar: Monday April 6 - Friday April 10	FW

06-16	ENORAMA PHARMA: BULLETIN FROM THE ANNUAL GENERAL MEETING OF ENORAMA PHARMA AB (PUBL)	AQ
05-13	Notice of annual general meeting of Enorama Pharma AB (publ)	AQ
04-07	Enorama Pharma: PRESS RELEASE FROM THE EXTRAORDINARY GENERAL MEETING, AND FIRST CONTROL MEETING, IN ENORAMA PHARMA AB (PUBL)	AQ
03-03	Enorama Pharma AB (publ) resolves to postpone the planned extraordinary general meeting	AQ
02-23	Bulletin from the extraordinary general meeting of Intellego Technologies AB (publ)	AQ

Enorama Pharma AB Stock

Stocks

ERMA

SE0008216329

Pharmaceuticals

Valuation: Enorama Pharma AB

Chart: Enorama Pharma AB

Latest news: Enorama Pharma AB

Press Releases: Enorama Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors: Enorama Pharma AB

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-17.55%
1 week	+19.73%
Current month	+34.05%
1 month	+19.07%
3 months	+150.43%
6 months	+224.91%
Current year	-54.24%

1 week	0.74	1.5
1 month	0.3	1.5
Current year	0.21	2.47
1 year	0.21	2.86
3 years	0.21	10.5
5 years	0.21	28.95
10 years	0.21	177

Manager	Title	Age	Since
Bengt Jönsson CEO	Chief Executive Officer	64	2025-11-10
Jonas Brisland DFI	Director of Finance/CFO	-	2025-08-31

Director	Title	Age	Since
Carl Olsson BRD	Director/Board Member	64	2022-12-31
Bengt Jönsson CHM	Chairman	64	2023-12-31
Tanu Tandan BRD	Director/Board Member	67	2023-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENORAMA PHARMA AB	-17.55%	+19.73%	-68.90%	-76.57%	7.99M
ELI LILLY AND COMPANY	+2.83%	+4.40%	+60.84%	+126.60%	1,133B
JOHNSON & JOHNSON	+3.81%	+5.66%	+38.70%	+76.77%	621B
ABBVIE INC.	+0.14%	+0.63%	+24.71%	+97.05%	503B
ROCHE HOLDING AG	+0.03%	+5.72%	+39.64%	+64.06%	379B
MERCK & CO., INC.	-1.76%	+1.41%	+68.06%	+42.47%	370B
NOVARTIS AG	+1.58%	+5.07%	+23.26%	+51.98%	292B
ASTRAZENECA PLC	+2.90%	+5.53%	+4.06%	+24.45%	262B
AMGEN INC.	+2.04%	+3.05%	+51.12%	+63.80%	237B
GILEAD SCIENCES, INC.	+2.36%	-0.11%	+29.42%	+102.67%	190B
Average	-0.47%	+7.42%	+27.09%	+57.33%	398.8B
Weighted average by Cap.	+1.69%	+3.73%	+42.92%	+84.30%

	2024	2025
Net sales	15.77M 1.59M 1.42M 1.31M 1.19M 2.23M 151M 2.27M 6.21M 78.88M 5.97M 5.84M 250M	2.74M 276K 246K 227K 207K 388K 26.15M 393K 1.08M 13.7M 1.04M 1.01M 43.41M
Net income	-43.81M -4.42M -3.94M -3.64M -3.3M -6.2M -418M -6.29M -17.26M -219M -16.58M -16.22M -694M	-75.14M -7.57M -6.76M -6.24M -5.67M -10.63M -717M -10.79M -29.6M -376M -28.43M -27.82M -1.19B
Net Debt	-2.08M -210K -188K -173K -157K -295K -19.91M -300K -821K -10.43M -789K -772K -33.04M	-3.04M -306K -273K -252K -229K -430K -29M -436K -1.2M -15.19M -1.15M -1.12M -48.13M